lumos.png
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
July 23, 2024 16:05 ET | Lumos Pharma, Inc.
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second...
Sanofi new_logo.jpg
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Juin 2024
July 22, 2024 16:05 ET | Sanofi - Aventis Groupe
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
Sanofi new_logo.jpg
Sanofi: Information concerning the total number of voting rights and shares – June 2024
July 22, 2024 16:05 ET | Sanofi - Aventis Groupe
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
Alvotech_logo.jpg
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
July 22, 2024 06:30 ET | Alvotech
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
nufarm.jpg
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
July 17, 2024 18:45 ET | Nufarm
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina.
22157.jpg
Industrial Roboverse in F&B and Pharmaceutical Markets, 2024 Research - Opportunities in Collaborative Robots, Warehouse Automation, and AI-driven Robots
July 17, 2024 05:36 ET | Research and Markets
Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Industrial Roboverse Growth Opportunities in the F&B and Pharmaceutical Industries" report has been added to ResearchAndMarkets.com's...
Aclaris_Logo_CLR®.jpg
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
July 16, 2024 16:01 ET | Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Lynch Carpenter Logo-01.png
Lynch Carpenter Investigates Claims in Rite Aid Data Breach
July 16, 2024 14:57 ET | Lynch Carpenter
PITTSBURGH, July 16, 2024 (GLOBE NEWSWIRE) -- Rite Aid Corporation (“Rite Aid”) recently announced that it suffered from a data breach which impacted the personal information of approximately 2.2...
Targretin Main Life
万联行获得Targretin®(Bexarotene 贝沙罗汀)在香港用于皮肤T细胞淋巴瘤的市场批准
July 16, 2024 02:54 ET | MAIN LIFE CORPORATION LIMITED
香港和澳门的批准标志着Targretin®首次在中国上市贝沙罗汀代表国际临床实践中对复发性皮肤T细胞淋巴瘤(CTCL)的标准治疗 香港, July 16, 2024 (GLOBE NEWSWIRE) -- 万联行有限公司(“Main Life”)今天宣布Targretin®(贝沙罗汀)胶囊在香港获得上市许可,用于治疗至少一次系统治疗无效的皮肤T细胞淋巴瘤 (Cutaneous T-cell...